Chimerix antiviral drug fails in late-stage study

(Reuters) - Chimerix Inc said its oral antiviral drug did not significantly reduce a certain kind of infection in stem cell transplant patients in a late-stage study, sending its shares down 72 percent in premarket trading.

http://ift.tt/1Ps7KUu

from Reuters: Health News
via animenewspro